Free Trial
NASDAQ:CRBU

Caribou Biosciences (CRBU) Stock Price, News & Analysis

Caribou Biosciences logo
$1.74 +0.15 (+9.06%)
As of 12:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Caribou Biosciences Stock (NASDAQ:CRBU)

Key Stats

Today's Range
$1.60
$1.76
50-Day Range
$0.75
$1.60
52-Week Range
$0.66
$3.00
Volume
1.33 million shs
Average Volume
1.33 million shs
Market Capitalization
$162.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Caribou Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

CRBU MarketRank™: 

Caribou Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 602nd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Caribou Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Caribou Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Caribou Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.64) to ($1.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Caribou Biosciences is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Caribou Biosciences is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Caribou Biosciences has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Caribou Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    13.52% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently increased by 31.29%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Caribou Biosciences does not currently pay a dividend.

  • Dividend Growth

    Caribou Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.52% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 9.7.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently increased by 31.29%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Caribou Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Caribou Biosciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 3 people have searched for CRBU on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Caribou Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Caribou Biosciences is held by insiders.

  • Percentage Held by Institutions

    77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Caribou Biosciences' insider trading history.
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CRBU Stock News Headlines

Top Picks for Trump’s Pro-Crypto America
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
CRBU Caribou Biosciences, Inc. - Seeking Alpha
See More Headlines

CRBU Stock Analysis - Frequently Asked Questions

Caribou Biosciences' stock was trading at $1.59 at the start of the year. Since then, CRBU stock has increased by 8.5% and is now trading at $1.7250.

Caribou Biosciences, Inc. (NASDAQ:CRBU) issued its earnings results on Thursday, May, 8th. The company reported ($0.43) EPS for the quarter, meeting analysts' consensus estimates of ($0.43). The company had revenue of $2.35 million for the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative net margin of 1,490.84% and a negative trailing twelve-month return on equity of 55.70%.

Caribou Biosciences (CRBU) raised $202 million in an IPO on Friday, July 23rd 2021. The company issued 13,500,000 shares at a price of $14.00-$16.00 per share.

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
5/08/2025
Today
7/09/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRBU
CIK
1619856
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$14.00
Low Price Target
$3.00
Potential Upside/Downside
+431.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$149.10 million
Net Margins
-1,490.84%
Pretax Margin
-1,490.94%

Debt

Sales & Book Value

Annual Sales
$9.99 million
Price / Cash Flow
N/A
Book Value
$2.79 per share
Price / Book
0.57

Miscellaneous

Free Float
84,170,000
Market Cap
$148.80 million
Optionable
Optionable
Beta
2.48
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:CRBU) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners